Trial Profile
Phase II Trial of Paclitaxel Combined With Trastuzumab and Pertuzumab as Pre-Operative Therapy for Inflammatory Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Doxorubicin
- Indications Early breast cancer; HER2 positive breast cancer; Inflammatory breast cancer; Male breast cancer
- Focus Therapeutic Use
- 17 Jul 2023 Planned End Date changed from 1 Mar 2023 to 1 Mar 2024.
- 02 May 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.
- 09 Aug 2021 Planned End Date changed from 1 Mar 2020 to 1 Mar 2022.